VIA
ALBO

Vantage Investment Advisors’s Albireo Pharma Inc ALBO Stock Holding History

Vantage Investment Advisors’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$4K – 818
2018
Q2 		$4K Sell
100
-100
-50% -$3.24K ﹤0.01% 665
2018
Q1 		$7K Buy
+200
New +$6.73K ﹤0.01% 620

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vantage Investment Advisors's ALBO Position: Q3 2018 in Review

Vantage Investment Advisors sold out of Albireo Pharma Inc (ALBO) in Q3 2018, closing a stake of 100 shares — an estimated $4K sold.

Vantage Investment Advisors first reported a position in ALBO in Q1 2018 and held it in 2 quarters. The position peaked at $7K in Q1 2018. 67 funds tracked by Wall St. Rank hold ALBO as of Q3 2018.

  • Vantage Investment Advisors reported no remaining Albireo Pharma Inc position as of Q3 2018 after selling out during the quarter.
  • Vantage Investment Advisors sold 100 Albireo Pharma Inc shares in Q3 2018, an estimated $4K.
  • Vantage Investment Advisors first reported a position in Albireo Pharma Inc in Q1 2018 and held it in 2 quarters.
  • Vantage Investment Advisors's Albireo Pharma Inc position peaked at $7K in Q1 2018.
  • 67 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.